Swedish biopharmaceutical company Modus Therapeutics Holding has raised Skr32m ($3.6m) from its existing investors, including KDev Investments, Ostersjostiftelsen and Praktikerinvest.

The funds will be utilised for the further development of the company’s drug sevuparin, which targets sickle cell disease.

Mercachem, a custom organic chemical compounds manufacturer based in the Netherlands, and UbiQ Bio, a biotechnology company also based in the Netherlands, have formed a joint venture (JV) known as SumiQ Therapeutics.

The JV will develop a therapy for Myc-driven cancers.

With the aim of expanding its European life science portfolio, Hong Kong-based private equity firm Ally Bridge Group has announced an investment in Nabriva Therapeutics.

Nabriva is a Austrian-based, clinical-stage biopharmaceutical company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"Canadian biotechnology company Arch Biopartners plans to raise up to C$0.4m ($0.31m) through a non-brokered private placement of one million common shares."

Canadian biotechnology company Arch Biopartners plans to raise up to C$0.4m ($0.31m) through a non-brokered private placement of one million common shares.

The shares will be priced at C$0.4 ($0.31) each and have a holding period of four months and one day from the closing date of the offering.

The proceeds will be used for the ongoing commercial development of the company’s drug candidate, AB569.

US-based biopharmaceutical company Global Blood Therapeutics has announced it intends to raise $75m in gross proceeds from a registered underwritten public offering of shares of its common stock, in order to primarily fund the clinical development of GBT440 for multiple indications.

Part of the funds will also be utilised for research and development (R&D), working capital and general corporate purposes.

Underwriters to the offering are also granted a 30-day option to buy up to an additional $11.25m-worth shares in order to cover over-allotment, if any.